Jun 09, 2023 (AB Digital via COMTEX) — The Opium Addiction market growth is driven by factors like increase in the prevalence …

Today, Daniel Cameron, Attorney General for the US State of Kentucky, announced that the State will take $42 million from its portion …

Deborah Mash is Professor of Neurology (Emeritus) and Molecular and Cellular Pharmacology at the University of Miami Miller School of Medicine. She …

If you or a loved one struggle with addiction, this is an episode you’re going to want to listen to.  Many of …

Source: https://www.benzinga.com/markets/cannabis/22/06/27799330/10-psychedelics-ceos-to-pay-attention-to-in-2022-1 2020 and 2021 were defining years for the burgeoning psychedelics industry. In 2021 alone, more than $730 million were invested into various …

People seeking treatment to overcome opioid addiction are often stymied by the treatment itself. Many don’t have access to drugs like methadone …

Anne Phillipi of The New Health Club presents Dr. Deborah Mash – ibogaine can make you review your life Posted at 12:01h in Podcast by demerx …

DemeRx IB, Inc. CEO Deborah Mash joined Proactive New York to discuss the group’s joint venture with Atai Life Sciences (NASDAQ:ATAI), focused …

Source: https://www.healtheuropa.com/could-ibogaine-offer-a-revolutionary-long-term-solution-to-addiction/100635/ Derived from the iboga plant, ibogaine is a psychoactive compound that could have huge potential as a long-term solution to …

Yale Psychedelics Science Group presents Dr. Deborah Mash – Breaking the Cycle of Opioid Dependence with ibogaine Watch full webinar: 

Today’s episode features Deborah Mash, founder and CEO of DemeRx, a clinical stage company developing ibogaine therapies to treat substance use disorders. In this …

A joint venture between DemeRx and Atai Life Sciences has been cleared by the UK Medicines and Healthcare products Regulatory Agency (MHRA) …

NEW YORK, March 10, 2021 /PRNewswire/ — DemeRx IB, Inc. (DemeRx), an atai Life Sciences (atai) platform company focused on developing ibogaine for the treatment …

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved the launch of a Phase I/IIa trial of DemeRx and atai …

2020 has been a tough year for global markets and this is a trend that we have been closely following. During the …

CEO and co-founder of ATAI Life Sciences, Florian Brand explains why one psychedelic medicine might provide the key to fighting opioid addiction. …

“ibogaine made them ready for change,” says researcher Deborah Mash, PhD. Mash has been studying the effects of ibogaine since 1992. A psychedelic …

BERLIN and MIAMI, Jan. 24, 2020 /PRNewswire/ — ATAI Life Sciences AG (“ATAI” or the “Company”), a global biotech platform that envisions an end to mental illnesses, today announced …

INTERNATIONAL – The World Economic Forum’s billionaire audience in Davos took a break from the problem of climate change to listen to …

Ira Pastor, ideaXme exponential health ambassador and founder of Bioquark interviews Dr. Deborah Mash, Professor of Neurology and Molecular and Cellular Pharmacology at the Leonard M. Miller School …

The United States is struggling with a staggering opioid addiction epidemic—often starting with legitimate pain pill prescriptions, and ending with full-blown abuse. …

When Dr. Deborah Mash met the grandfather of ibogaine treatment, Howard Lotsof, and observed first-hand the effectiveness that ibogaine had for addiction …

Heroin addicts and alcoholics have said ibogaine helped them kick addiction, so why is it illegal in the United States? Read full …

News from Kron 4, San Fransisco. Dr. Mash is one of the few scientists in the world to study ibogaine, a mild …